Akari Therapeutics (AKTX) Liabilities and Shareholders Equity (2011 - 2026)

Akari Therapeutics has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $33.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $33.9 million, down 33.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $178.1 million (up 62.87% YoY), and the FY2025 annual result was $47.9 million, down 5.28% from the prior year.
• Liabilities and Shareholders Equity came in at $33.9 million for Q1 2026 at Akari Therapeutics, down from $47.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $51.0 million in Q1 2025 to a low of $2.7 million in Q3 2024.
• The 5-year median for Liabilities and Shareholders Equity is $33.9 million (2026), against an average of $28.0 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 68.52% in 2023 and jumped 1738.35% in 2025, its largest moves.
• Akari Therapeutics' Liabilities and Shareholders Equity stood at $13.8 million in 2022, then slumped by 68.52% to $4.4 million in 2023, then jumped by 1061.01% to $50.6 million in 2024, then declined by 5.28% to $47.9 million in 2025, then retreated by 29.24% to $33.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $33.9 million (Q1 2026), $47.9 million (Q4 2025), and $45.4 million (Q3 2025), per Business Quant data.